AbbVie (NYSE:ABBV) Reaches New 52-Week High – Here’s Why

AbbVie Inc. (NYSE:ABBV)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $268.41 and last traded at $266.4530, with a volume of 189319 shares traded. The stock had previously closed at $265.21.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Rinvoq received EU approval for children with juvenile arthritis. The European Commission approved Rinvoq (upadacitinib) for patients aged two and older with active polyarticular juvenile idiopathic arthritis who inadequately responded to, or could not tolerate, standard DMARD treatment. The approval adds a pediatric indication, an oral-solution formulation and Rinvoq’s 11th indication in the European Union. While the market opportunity is relatively small, the decision broadens the drug’s commercial reach and supports AbbVie’s effort to sustain Rinvoq growth. Approval was supported by the SELECT-YOUTH study and adult rheumatoid arthritis data. AbbVie Announces European Commission Approval of Rinvoq
• Positive Sentiment: AbbVie entered a multiyear AI drug-discovery collaboration with Iambic. The companies plan to use Iambic’s artificial-intelligence platform to identify and develop small-molecule therapies in immunology, neuroscience and oncology. The agreement could improve research efficiency and strengthen AbbVie’s longer-term pipeline, though it carries development risk and is unlikely to materially affect near-term earnings. AbbVie and Iambic Announce Collaboration
• Positive Sentiment: Allergan Aesthetics launched its AA Signature SKIN360 program in the U.S. The multimodal consultation and provider-education initiative is intended to support more comprehensive aesthetic treatments, potentially reinforcing AbbVie’s aesthetics franchise and patient engagement. Allergan Aesthetics Debuts AA Signature

Analyst Upgrades and Downgrades

Several analysts have issued reports on ABBV shares. Canaccord Genuity Group upped their target price on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Guggenheim upped their price target on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Wells Fargo & Company upped their price target on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. UBS Group boosted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Finally, Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $276.64.

AbbVie Stock Up 0.2%

The company’s 50 day moving average price is $256.31 and its two-hundred day moving average price is $232.58. The stock has a market cap of $469.55 billion, a P/E ratio of 75.15, a P/E/G ratio of 1.19 and a beta of 0.29.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. AbbVie’s dividend payout ratio is presently 195.48%.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On AbbVie

A number of institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of AbbVie during the fourth quarter valued at $5,865,055,000. Corient Private Wealth LP acquired a new position in shares of AbbVie during the second quarter worth about $559,736,000. Legal & General Group Plc purchased a new stake in AbbVie during the 2nd quarter worth $2,905,952,000. Capital World Investors boosted its stake in shares of AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after buying an additional 6,736,161 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new position in AbbVie in the second quarter worth about $1,560,354,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.